Vienna, March 16, 2020 On Wednesday March 11 the World Health Organization (WHO) announced a pandemic in response to the COVID-19 outbreak. This is a serious health situation influencing numerous countries worldwide. We want to...

vairāk par "AOP Orphan Statement on SARS-CoV-2 and COVID-19"

BESREMi® is approved as first-line monotherapy in adults for the treatment of Polycythaemia vera (PV) without symptomatic splenomegaly BESREMi® showed high and durable hematologic response, molecular response and disease...

more about "AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV) "

AOP Orphan Pharmaceuticals AG, the Austrian specialist for rare diseases, will implement ‘Mobile IntelligenceTM (MI)’ - the smart CRM Tool from leading Life-Sciences consultant, IQVIA.

vairāk par "AOP Orphan to implement innovative CRM system in collaboration with IQVIA Austria "

Bioprojet Pharma SAS and AOP Orphan Pharmaceuticals AG (AOP Orphan) entered a distribution agreement for Wakix®The covered territory includes mainly Central and Northern European countriesWakix® is approved for treatment of...

vairāk par "AOP Orphan will distribute Wakix® (pitolisant) from Bioprojet Pharma SAS in Austria, Nordic countries and Central Eastern Europe"

AOP Orphan supports the Christian Doppler Laboratory for Iron Metabolism and Anemia Research at the Medical University of Innsbruck, Austria, opening on January 31st, 2018. To read the full press release in German, please click...

vairāk par "The Medical University of Innsbruck: Christian Doppler Laboratory for Iron Metabolism and Anemia Research is opened."

Uzņēmums AOP Orphan Pharmaceuticals AG šodien ir paziņojis, ka tam ir izdevies iegūt selisistatu – ļoti selektīvu SIRT1 inhibitoru, kura eksperimentālajos pētījumos ir novērotas iespējamas slimību modificējošas īpašības, kas var...

vairāk par "AOP Orphan Pharmaceuticals AG savā īpašumā iegūst Hantingtona slimības ārstēšanai paredzētas klīniskās izstrādes fāzē esošas kandidātzāles selisistatu"

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances,  which was published recently in...

vairāk par "Austria as a Research & Development base"

Cancer Drug News 733

vairāk par "AOP in Press: "New Therapies To Struggle Against Established Hematology""

Īstās policitēmijas slimnieku ilgstoša balstterapija ar alfa-2b ropeginterferonu, lietojot ik pēc 4 nedēļām, ir lietderīga, efektīva un labi panesama.Individuālu devu pašievadīšana mājas apstākļos, izmantojot pildspalvveida...

vairāk par "AOP Orphan un PharmaEssentia informē par jaunākajiem alfa-2b ropeginterferona klīniskajiem rezultātiem īstās policitēmijas ārstēšanā no 3 kopsavilkumiem, kas prezentēti 22. Eiropas Hematologu asociācijas (EHA) kongresā Madridē"

AOP Orphan Pharmaceuticals AG (AOP Orphan) šodien paziņoja, ka viņu izplatīšanas partneris Amomed Pharma GmbH (Amomed) 19. jūnijā sāk RAPIBLOC® (Rapibloc, 300 mg pulveris infūziju šķīduma pagatavošanai) komercializēšanu, kas...

vairāk par "AOP Orphan Pharmaceuticals AG un Amomed Pharma GmbH paziņo par RAPIBLOC® (landiolola) ienākšanu Vācijas un Austrijas tirgū"

Nesen Austrijas laikraksta “derStandard” īpaši izdotā pielikumā “CURE” publicēta intervija ar ģenerāldirektoru Dr. Rūdolfu Vidmanu (Widmann) un zinātnes attīstības direktoru Dr. Kristofu Klādi (Klade) par “AOP Orphan” apņemšanos...

vairāk par "Retās slimības: Akciju sabiedrība “AOP Orphan Pharmaceuticals” investē ilgtspējīgā pētniecībā un attīstībā"

Highlights: Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe.Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme...

more about "AOP Orphan Pharmaceuticals AG announces European “approvable” opinion of its ultra-short acting beta blocker Rapibloc® (Landiolol)"

As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts...

more about "Innovative antipsychotic ADASUVE® to benefit even more patients"

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®, developed by Cardiome Pharma Corp., Canada, in Central Europe....

more about "AOP Orphan to market the innovative antiarrhythmic drug BRINAVESS® exclusively in Central Europe"

The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...

more about "Internationally renowned pharmaceutical expert Hans Peter Hasler strengthens AOP Orphan Supervisory Board"

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.

more about "Partnership between AOP Orphan and Ferrer: Joint marketing of Adasuve® in CEE"

AOP Orphan announces progress of pan-European phase III trial PROUD-PV to support European Marketing Authorization of AOP2014/P1101, a next-generation, mono-pegylated Interferon alpha 2b.

more about "AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV of novel mono-pegylated Interferon alpha 2b for the treatment of Polycythemia vera"